drugset / Trial / NCT07328022

Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

NCT07328022

Phase 3 Completed 89 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.

Timeline

Start
2025-05-14
Primary completion
2025-08-20
Completion
2025-11-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.25 mg Oral
Comparator Etoricoxib Small molecule 90 mg Oral